GLOBUS MEDICAL INC - A (GMED) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:GMED - US3795772082 - Common Stock
88.43 USD
-0.34 (-0.38%)
88.43 USD
0 (0%)
Overall GMED gets a fundamental rating of 6 out of 10. We evaluated GMED against 185 industry peers in the Health Care Equipment & Supplies industry. GMED has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GMED is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, GMED could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year GMED was profitable.
In the past year GMED had a positive cash flow from operations.
In the past 5 years GMED has always been profitable.
In the past 5 years GMED always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.32%, GMED belongs to the top of the industry, outperforming 90.27% of the companies in the same industry.
The Return On Equity of GMED (9.63%) is better than 84.86% of its industry peers.
GMED has a better Return On Invested Capital (8.29%) than 85.41% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for GMED is below the industry average of 8.82%.
The last Return On Invested Capital (8.29%) for GMED is above the 3 year average (5.79%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.32% | ||
| ROE | 9.63% | ||
| ROIC | 8.29% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)5.79%
ROIC(5y)6.37%
1.3 Margins
The Profit Margin of GMED (15.30%) is better than 91.35% of its industry peers.
GMED's Profit Margin has declined in the last couple of years.
GMED has a better Operating Margin (17.37%) than 88.65% of its industry peers.
GMED's Operating Margin has declined in the last couple of years.
GMED has a better Gross Margin (67.05%) than 70.81% of its industry peers.
GMED's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.37% | ||
| PM (TTM) | 15.3% | ||
| GM | 67.05% |
OM growth 3Y-23.93%
OM growth 5Y-16.84%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-7.75%
GM growth 5Y-5.24%
2. Health
2.1 Basic Checks
GMED has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, GMED has more shares outstanding
GMED has more shares outstanding than it did 5 years ago.
GMED has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 11.74 indicates that GMED is not in any danger for bankruptcy at the moment.
GMED has a Altman-Z score of 11.74. This is amongst the best in the industry. GMED outperforms 90.27% of its industry peers.
GMED has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
The Debt to FCF ratio of GMED (0.00) is better than 94.59% of its industry peers.
GMED has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
GMED has a better Debt to Equity ratio (0.00) than 76.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.74 |
ROIC/WACC0.96
WACC8.65%
2.3 Liquidity
GMED has a Current Ratio of 4.13. This indicates that GMED is financially healthy and has no problem in meeting its short term obligations.
GMED's Current ratio of 4.13 is fine compared to the rest of the industry. GMED outperforms 69.73% of its industry peers.
A Quick Ratio of 2.47 indicates that GMED has no problem at all paying its short term obligations.
GMED's Quick ratio of 2.47 is in line compared to the rest of the industry. GMED outperforms 58.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.13 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.76% over the past year.
Measured over the past years, GMED shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.19% on average per year.
Looking at the last year, GMED shows a quite strong growth in Revenue. The Revenue has grown by 11.75% in the last year.
GMED shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.25% yearly.
EPS 1Y (TTM)22.76%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%42.17%
Revenue 1Y (TTM)11.75%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%22.91%
3.2 Future
The Earnings Per Share is expected to grow by 10.62% on average over the next years. This is quite good.
GMED is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.32% yearly.
EPS Next Y23.2%
EPS Next 2Y15.66%
EPS Next 3Y13.29%
EPS Next 5Y10.62%
Revenue Next Year15.07%
Revenue Next 2Y11.62%
Revenue Next 3Y9.81%
Revenue Next 5Y8.32%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 24.84, which indicates a rather expensive current valuation of GMED.
Based on the Price/Earnings ratio, GMED is valued a bit cheaper than the industry average as 77.84% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of GMED to the average of the S&P500 Index (26.59), we can say GMED is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 21.05, the valuation of GMED can be described as rather expensive.
GMED's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. GMED is cheaper than 80.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.03, GMED is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.84 | ||
| Fwd PE | 21.05 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMED indicates a rather cheap valuation: GMED is cheaper than 81.62% of the companies listed in the same industry.
88.11% of the companies in the same industry are more expensive than GMED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.77 | ||
| EV/EBITDA | 15.09 |
4.3 Compensation for Growth
GMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
GMED has a very decent profitability rating, which may justify a higher PE ratio.
GMED's earnings are expected to grow with 13.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.07
PEG (5Y)1.88
EPS Next 2Y15.66%
EPS Next 3Y13.29%
5. Dividend
5.1 Amount
No dividends for GMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
88.43
-0.34 (-0.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners108.24%
Inst Owner Change1.95%
Ins Owners0.68%
Ins Owner Change1.38%
Market Cap11.84B
Revenue(TTM)2.77B
Net Income(TTM)423.78M
Analysts77.14
Price Target94.58 (6.95%)
Short Float %3.98%
Short Ratio2.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.7%
Min EPS beat(2)11.6%
Max EPS beat(2)47.79%
EPS beat(4)3
Avg EPS beat(4)14.87%
Min EPS beat(4)-10.39%
Max EPS beat(4)47.79%
EPS beat(8)6
Avg EPS beat(8)14.29%
EPS beat(12)9
Avg EPS beat(12)10.13%
EPS beat(16)11
Avg EPS beat(16)6.78%
Revenue beat(2)1
Avg Revenue beat(2)0.59%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)-1.24%
Min Revenue beat(4)-6.31%
Max Revenue beat(4)2.67%
Revenue beat(8)5
Avg Revenue beat(8)-0.3%
Revenue beat(12)7
Avg Revenue beat(12)-0.72%
Revenue beat(16)8
Avg Revenue beat(16)-0.84%
PT rev (1m)15.48%
PT rev (3m)12.33%
EPS NQ rev (1m)2.52%
EPS NQ rev (3m)21.35%
EPS NY rev (1m)18.34%
EPS NY rev (3m)18.25%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)0.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.84 | ||
| Fwd PE | 21.05 | ||
| P/S | 4.27 | ||
| P/FCF | 20.77 | ||
| P/OCF | 16.55 | ||
| P/B | 2.69 | ||
| P/tB | 5.4 | ||
| EV/EBITDA | 15.09 |
EPS(TTM)3.56
EY4.03%
EPS(NY)4.2
Fwd EY4.75%
FCF(TTM)4.26
FCFY4.82%
OCF(TTM)5.34
OCFY6.04%
SpS20.69
BVpS32.87
TBVpS16.37
PEG (NY)1.07
PEG (5Y)1.88
Graham Number51.31
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.32% | ||
| ROE | 9.63% | ||
| ROCE | 10.39% | ||
| ROIC | 8.29% | ||
| ROICexc | 9.06% | ||
| ROICexgc | 18.9% | ||
| OM | 17.37% | ||
| PM (TTM) | 15.3% | ||
| GM | 67.05% | ||
| FCFM | 20.58% |
ROA(3y)4.51%
ROA(5y)5.45%
ROE(3y)5.28%
ROE(5y)6.24%
ROIC(3y)5.79%
ROIC(5y)6.37%
ROICexc(3y)7.27%
ROICexc(5y)8.25%
ROICexgc(3y)12.85%
ROICexgc(5y)12.55%
ROCE(3y)7.25%
ROCE(5y)7.98%
ROICexgc growth 3Y0.63%
ROICexgc growth 5Y-2.08%
ROICexc growth 3Y-23.17%
ROICexc growth 5Y-16.59%
OM growth 3Y-23.93%
OM growth 5Y-16.84%
PM growth 3Y-35.97%
PM growth 5Y-27.03%
GM growth 3Y-7.75%
GM growth 5Y-5.24%
F-Score9
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 52.62% | ||
| Cap/Sales | 5.24% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 94.46% | ||
| Profit Quality | 134.49% | ||
| Current Ratio | 4.13 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z | 11.74 |
F-Score9
WACC8.65%
ROIC/WACC0.96
Cap/Depr(3y)69.29%
Cap/Depr(5y)78.11%
Cap/Sales(3y)5.6%
Cap/Sales(5y)6.16%
Profit Quality(3y)194.29%
Profit Quality(5y)172.4%
High Growth Momentum
Growth
EPS 1Y (TTM)22.76%
EPS 3Y15.46%
EPS 5Y13.19%
EPS Q2Q%42.17%
EPS Next Y23.2%
EPS Next 2Y15.66%
EPS Next 3Y13.29%
EPS Next 5Y10.62%
Revenue 1Y (TTM)11.75%
Revenue growth 3Y38.03%
Revenue growth 5Y26.25%
Sales Q2Q%22.91%
Revenue Next Year15.07%
Revenue Next 2Y11.62%
Revenue Next 3Y9.81%
Revenue Next 5Y8.32%
EBIT growth 1Y109.04%
EBIT growth 3Y5%
EBIT growth 5Y5%
EBIT Next Year69.22%
EBIT Next 3Y26.34%
EBIT Next 5Y17.51%
FCF growth 1Y341.47%
FCF growth 3Y22.69%
FCF growth 5Y31.98%
OCF growth 1Y252.66%
OCF growth 3Y23.51%
OCF growth 5Y24.8%
GLOBUS MEDICAL INC - A / GMED FAQ
What is the ChartMill fundamental rating of GLOBUS MEDICAL INC - A (GMED) stock?
ChartMill assigns a fundamental rating of 6 / 10 to GMED.
What is the valuation status for GMED stock?
ChartMill assigns a valuation rating of 5 / 10 to GLOBUS MEDICAL INC - A (GMED). This can be considered as Fairly Valued.
Can you provide the profitability details for GLOBUS MEDICAL INC - A?
GLOBUS MEDICAL INC - A (GMED) has a profitability rating of 7 / 10.
What is the valuation of GLOBUS MEDICAL INC - A based on its PE and PB ratios?
The Price/Earnings (PE) ratio for GLOBUS MEDICAL INC - A (GMED) is 24.84 and the Price/Book (PB) ratio is 2.69.
What is the financial health of GLOBUS MEDICAL INC - A (GMED) stock?
The financial health rating of GLOBUS MEDICAL INC - A (GMED) is 7 / 10.